Wow, that looks really promising. I'm a little concerned that its just directed to menopausal women though. I'm sure there's a lot of men who could benefit too. I'm also sure we could convince a doctor to prescribe it to us though. Not a whole lot of downside !
2014 market release date? Brutal! I can see being very cautious with a heart pill, but an eyelid cream ?
Still gives us some optimism though.
-
Some treatments directed at hormones in the pipelines:
http://www.argentisrx.com/content/show.asp?mne=pipeline
"ARG101 is a testosterone cream or gel formulation used to treat DES in menopausal women. Waning androgen levels in women before, during, and after menopause has been identified as a primary cause of DES in this population. ARG101 is unique in that it is applied to the upper and lower eyelids for transdermal delivery of testosterone directly to the affected glands. Delivering the active pharmaceutical ingredient transdermally allows better access to the glands and enables convenient twice-daily dosing. ARG101 restores aqueous and lipid production thereby restoring the natural process of tear production.
Clinical practice at the Southern College of Optometry (SCO) has documented ARG101 efficacy and safety. Patients using ARG101 achieved a 51% increase in aqueous secretion (p=0.01) and a 68% increase in tear breakup time, a measure of meibomian gland function, versus baseline measurements. There was also a 51% (p=0.01) decrease in symptoms as measured by the Ocular Severity Disease Index (OSDI), a validated measure of DES symptoms. There have been no adverse events and, importantly, no increase in intraocular pressure in patients using the testosterone cream for three years. Results of the use of testosterone in patients at SCO have been presented at the Annual Meeting of the American Association of Optometrists in each year 2002-2006.
ARG102 is a progesterone cream or gel formulation used to treat DES in men and younger women. The cross-reactivity between progesterone and corticosteroid receptors in the ocular region is believed to activate corticosteroid anti-inflammatory activity in the glands and on the ocular surface, restoring normal aqueous and lipid production. ARG102 is also applied to the upper and lower eyelids for transdermal delivery of progesterone directly to the affected glands.
Patient data from clinical practice at SCO has shown that patients using ARG102 had a 34% increase in tear breakup time (p=0.01) and a 20% decrease in symptom severity (p=0.05) after only three weeks of use versus baseline measurements. There were no reported adverse events or increases in intraocular pressure. These results were presented at the 2006 Annual Meeting of the American Association of Optometrists.
ARG103 is a combination of testosterone and progesterone in a cream or gel formulation used to treat previously untreated post-menopausal women. Anecdotal results from SCO have shown promise in treating these women who because of lack of treatment options may have more severe glandular dysfunction.
These treatments share several characteristics which make them unique among current DES therapies and those in development:
■A patient-friendly application with a cream or gel formulation to the outer upper and lower eyelids versus conventional drop application.
■Transdermal delivery of anti-inflammatory hormones directly to the affected glands.
■Restores the natural process of tear production versus tear replacement of conventional therapies.
■Convenient twice-daily dosing versus the frequent applications required by tear replacement therapies.
■No stinging or burning of the skin to which it is applied or of the ocular surface. "Leave a comment:
-
Progesterone & Testosterone eye drops
Anyone have any information about Progesterone & Testosterone drops? Found out the pharmacy who makes my C-serum tears, makes these drops and says people are having great results. Anyone else tried these? I am 100% convinced there is a hormone connection with dry eye. Especially in my case. Any input would be helpful.
Leave a comment: